A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes

ClinicalTrials.gov ID: NCT07748208

Public ClinicalTrials.gov record NCT07748208. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Prospective, Open-Label Safety Study of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With PIK3CA-Mutated Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer and Type 2 Diabetes

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will evaluate the safety of inavolisib in combination with fulvestrant, with or without palbociclib, in participants with PIK3CA-mutated, HR+, HER2-negative ABC and type 2 diabetes.

Study identification

NCT ID: NCT07748208
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Hoffmann-La Roche; Industry
Enrollment: 40 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 30, 2026 (Estimated)
Primary completion: Jun 15, 2029 (Estimated)
Completion: Sep 30, 2029 (Estimated)
Last update posted: Oct 20, 2026

2026 – 2029

United States locations

U.S. sites: 9
U.S. states: 5
U.S. cities: 7

Facility	City	State	ZIP	Site status
MedStar Washington Hosp Center	Washington D.C.	District of Columbia	20010	Recruiting
Grady Memorial Hospital	Atlanta	Georgia	30303-3031	Recruiting
Emory University Hospital Midtown	Atlanta	Georgia	30308-2212	Recruiting
Emory University Hospital	Atlanta	Georgia	30322	Recruiting
Nebraska Cancer Specialists St Francis - Grand Island	Grand Island	Nebraska	68803	Recruiting
Nebraska Cancer Specialists	Omaha	Nebraska	68114	Recruiting
NYU Langone Hospital Long Island Clinical Research	Mineola	New York	11501-4089	Recruiting
NYU Langone?s Perlmutter Cancer Center - 160 E 34th St	New York	New York	10016-4744	Recruiting
West Virginia University	Morgantown	West Virginia	26506-1200	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07748208, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 20, 2026 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT07748208 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →